Form 4: Guardant Health Director Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Guardant Health Director Tariq Musa sold 116 shares of common stock for $101.46 per share under a pre-arranged Rule 10b5-1 plan.
Summary
- Tariq Musa, a Director of Guardant Health, Inc. (GH), reported a sale of common stock.
- The transaction involved the disposition of 116 shares of Guardant Health common stock.
- The shares were sold at a price of $101.46 per share.
- The transaction occurred on December 17, 2025.
- Following this transaction, Tariq Musa beneficially owns 7,993 shares of Guardant Health common stock.
- The sale was executed pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Sentiment
Score: 5
Explanation: The filing reports a routine, pre-planned insider stock sale, which is generally neutral in sentiment. The use of a 10b5-1 plan is a positive for transparency, but the sale itself is a disposition of shares.
Positives
- The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-scheduled sale and not a reaction to recent non-public information, which enhances transparency and reduces concerns about opportunistic insider trading.
Negatives
- A director selling shares, even a small amount, could be perceived negatively by some investors, although the pre-arranged nature of the 10b5-1 plan mitigates this concern.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
This insider transaction is a routine disclosure and does not inherently reflect broader industry trends or competitive dynamics. Insider sales, especially those under 10b5-1 plans, are common and often relate to personal financial planning rather than company-specific news.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Policy Adherence | The transaction was executed under a Rule 10b5-1(c) plan, which is a pre-arranged trading plan designed to allow insiders to sell shares without being accused of trading on material non-public information. | 12/17/2025 | This demonstrates adherence to robust corporate governance practices regarding insider trading, promoting transparency and mitigating potential conflicts of interest. |
Stakeholder Impact
- Shareholders: A minor, pre-planned sale by a director is unlikely to have a significant direct impact on shareholders, though some may view any insider sale with caution. The 10b5-1 plan provides reassurance regarding the nature of the sale.
Key Dates
| Date | Description |
|---|---|
| 12/17/2025 | Date of common stock disposition by Tariq Musa. |
| 12/18/2025 | Date the Form 4 was signed and filed. |
Keywords
Guardant Health, GH, Insider Sale, Form 4, Tariq Musa, Director, Stock Transaction, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.